fda sued over tirzepatide Republican Administration Maintains Exclusivity Stance in GLP-1 (Tirzepatide) Compounding Dispute Trade group sues F.D.A. over

Who its for: People who prefer OTC options, cannot tolerate injectables, or want a medication that works locally in the gut rather than systemically

Most of these side effects are your bodys way of adjusting to slower digestion and reduced appetite core effects of how GLP-1s work

Current research and clinical experience generally indicate no specific harmful interactions (contraindications) between GLP-1 medications and common laxatives

Copies of some of the documents referred to herein have been filed as exhibits to this Annual Report

Russell, H

Results were published in the New England Journal of Medicine in May 2025